Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Phillips 66 enters the final stretch before its October 28 earnings with an unusual split: short sellers are covering, the stock is up 6.4% on the week, and yet the most prominent analyst move of the week is a downgrade.
Mizuho's Nitin Kumar cut the rating to Neutral from Outperform this morning, even as he lifted his price target sharply to $300 from $220. That combination captures the dilemma facing the stock perfectly: the fundamental case has improved materially, but at $271.62 the share price has now caught up with it. The prior note, published September 30, noted that the mean target sat at $255.58 with the stock near $252. Both figures have moved: PSX has pushed through $271, and the revised consensus target is around $257, putting the stock modestly above the Street's central estimate. Goldman Sachs raised its target to $274 on October 1 while holding Neutral. TD Cowen at $295 and Wells Fargo at $335 represent the high end of conviction, but Mizuho's move is the clearest signal that the upgrade cycle has reached a natural pause. EPS momentum scores rank in the 90th percentile over both 30 and 90 days, and the dividend score sits at 94, yet the 12-month forward EPS growth rank is just 31, reflecting genuine uncertainty about whether earnings can keep pace with the re-rating.
Short positioning has continued to ease, though it was never the dominant story here. Short interest fell to 1.6% of free float, down about 2.5% on the week and now roughly 37% above where it stood a month ago after a September rebuild. The borrow market remains effectively irrelevant to the thesis: availability is at its ceiling, with borrowing costs around 0.33% and no meaningful squeeze mechanics in play. Options positioning has rotated in a more interesting direction. The put/call ratio has dropped to 0.94, more than 1.3 standard deviations below its 20-day average of 1.04, and well below the levels that prevailed through most of September when the ratio ran above 1.10. Traders who were buying downside protection a few weeks ago have largely stepped back, a shift that fits with the stock's strong performance but may also reflect reduced hedging interest ahead of earnings rather than a clean bullish signal.
Elliott Management remains on the institutional register with roughly 4.8% of shares as last disclosed at end-June, unchanged from the prior reading. The activist register also carries a Schedule 13D filed in April by an entity called Link Co disclosing a 10% stake, though the filing is from April 3 and carries only one entry. As the disclosure note makes clear, 13D/G positions are event-driven around the 5% threshold and may not reflect current holdings. BlackRock added over two million shares in the period ending September 30 to reach 8.5% of shares, the largest single move among the top holders this quarter.
The peer group had a strong week too, which complicates the PSX-specific narrative. MPC gained 11.8% on the week and VLO rose 9.4%, meaning PSX's 6.4% move was actually the softer outcome among the closest refining comparables. That's a small reversal from the dramatic outperformance PSX logged across most of 2026. The bull case rests on WRB acquisition synergies, sub-$6/bbl controllable costs, and a gross debt reduction path toward $17 billion by year-end 2026. The bear case points to the $130 million CPChem earnings drag, a $1 billion working capital headwind, and balance sheet leverage that has kept PSX lagging the refining group on a 12-month relative return basis, a point that Mizuho's downgrade implicitly acknowledges.
The next earnings print on October 28 is 20 days away. After the most recent release in August the stock fell less than 0.2% on the day before recovering 9.6% over the subsequent five sessions, a pattern worth holding in mind as positioning data and analyst revisions accumulate into the print.
See the live data behind this article on ORTEX.
Open PSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
